

Lars Gullestad

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5235283/lars-gullestad-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210
papers

8,528
citations

44
h-index

87
g-index

221
ext. papers

9,965
ext. citations

5.4
avg, IF

5.47
L-index

#	Paper	IF	Citations
210	Diastolic Dysfunction Is Unmasked on Exercise in Patients With Asymptomatic, Severe Aortic Stenosis: An Invasive Hemodynamic Study.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121009253	7.6	0
209	Targeting the Inflammasome in Cardiovascular Disease.. <i>JACC Basic To Translational Science</i> , 2022 , 7, 84-98	8.7	8
208	Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo.. <i>Clinical Transplantation</i> , 2022 , e14695	3.8	
207	Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial.. <i>EBioMedicine</i> , 2022 , 80, 104013	8.8	1
206	Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 507-516	6.4	6
205	Microcirculatory Resistance Predicts Allograft Rejection and Cardiac Events After Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2425-2435	15.1	0
204	Comparing manual and automatic scoring of sleep monitoring data from portable polygraphy. <i>Journal of Sleep Research</i> , 2021 , 30, e13036	5.8	2
203	A randomized clinical study using optical coherence tomography to evaluate the short-term effects of high-intensity interval training on cardiac allograft vasculopathy: a HITS substudy. <i>Clinical Transplantation</i> , 2021 , e14488	3.8	
202	Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2021 , 111, 440	6.1	2
201	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 700-710	9.5	35
200	Circulating regulators of the wingless pathway in precapillary pulmonary hypertension. <i>Respirology</i> , 2021 , 26, 574-581	3.6	3
199	Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1845-1855	15.1	46
198	Outcomes in asymptomatic, severe aortic stenosis. <i>PLoS ONE</i> , 2021 , 16, e0249610	3.7	3
197	Symptoms of anxiety after heart transplantation and their association with mortality: A secondary analysis. <i>Clinical Transplantation</i> , 2021 , 35, e14323	3.8	0
196	Prevalence of iron deficiency in heart transplant recipients. <i>Clinical Transplantation</i> , 2021 , 35, e14346	3.8	1
195	Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction. <i>Open Heart</i> , 2021 , 8,	3	3
194	Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 359-367	5.8	5

193	Functional evidence of low-pressure cardiopulmonary baroreceptor reinnervation 1 year after heart transplantation. <i>European Journal of Applied Physiology</i> , 2021 , 121, 915-927	3.4	1
192	Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 405-419	15.1	21
191	Machine Learning for Sleep Apnea Detection with Unattended Sleep Monitoring at Home. <i>ACM Transactions on Computing for Healthcare</i> , 2021 , 2, 1-25	2.6	1
190	Rifaximin or <i>Saccharomyces boulardii</i> in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. <i>EBioMedicine</i> , 2021 , 70, 103511	8.8	7
189	Early Signs of Sinoatrial Reinnervation in the Transplanted Heart. <i>Transplantation</i> , 2021 , 105, 2086-2096	1.8	2
188	Effect of Continuous Positive Airway Pressure on Arrhythmia in Atrial Fibrillation and Sleep Apnea: A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 573-582	10.2	8
187	The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease. <i>Atherosclerosis</i> , 2021 , 336, 23-29	3.1	
186	NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. <i>JACC: Heart Failure</i> , 2021 , 9, 653-663	7.9	1
185	Reply: Safety of intravenous iron in heart transplant patients: Comment to paper by Brautaset Englund et al. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1247-1248	5.8	
184	Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation. <i>European Heart Journal</i> , 2021 ,	9.5	2
183	The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure.. <i>Frontiers in Immunology</i> , 2021 , 12, 800978	8.4	1
182	EBlocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. <i>Biomedicine Hub</i> , 2020 , 5, 9-18	1.3	0
181	Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. <i>Clinical Transplantation</i> , 2020 , 34, e13984	3.8	7
180	Long-term effects of high-intensity training vs moderate intensity training in heart transplant recipients: A 3-year follow-up study of the randomized-controlled HITTS study. <i>American Journal of Transplantation</i> , 2020 , 20, 3538-3549	8.7	3
179	Is the novel LDL-cholesterol goal . <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320923187	3.9	5
178	Effect of high-intensity interval training in young heart transplant recipients: results from two randomized controlled trials. <i>BMC Sports Science, Medicine and Rehabilitation</i> , 2020 , 12, 35	2.4	3
177	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. <i>ESC Heart Failure</i> , 2020 , 7, 567-576	3.7	1
176	Low fibre intake is associated with gut microbiota alterations in chronic heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 456-466	3.7	19

175	Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy. <i>Transplant International</i> , 2020 , 33, 517-528	3	2
174	Rosuvastatin alters the genetic composition of the human gut microbiome. <i>Scientific Reports</i> , 2020 , 10, 5397	4.9	8
173	Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages. <i>Atherosclerosis</i> , 2020 , 296, 74-82	3.1	4
172	Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. <i>Transplantation</i> , 2020 , 104, 154-164	1.8	12
171	Elevated levels of the secreted wingless agonist R-spondin 3 in preeclamptic pregnancies. <i>Journal of Hypertension</i> , 2020 , 38, 1347-1354	1.9	2
170	6 min walk test is a strong independent predictor of death in outpatients with heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 2904-2911	3.7	10
169	YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in Aortic Stenosis. <i>Circulation: Heart Failure</i> , 2020 , 13, e006643	7.6	0
168	Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an invasive versus conservative strategy: angiographic and procedural results from the After Eighty study. <i>Open Heart</i> , 2020 , 7,	3	1
167	Distinct patterns of soluble leukocyte activation markers are associated with etiology and outcomes in precapillary pulmonary hypertension. <i>Scientific Reports</i> , 2020 , 10, 18540	4.9	1
166	Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis. <i>EBioMedicine</i> , 2020 , 60, 102985	8.8	17
165	High-intensity interval training and health-related quality of life in de novo heart transplant recipients - results from a randomized controlled trial. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 283	3	6
164	Autonomic cardiovascular control changes in recent heart transplant recipients lead to physiological limitations in response to orthostatic challenge and isometric exercise. <i>European Journal of Applied Physiology</i> , 2019 , 119, 2225-2236	3.4	8
163	Statin-associated muscle symptoms in coronary patients: design of a randomized study. <i>Scandinavian Cardiovascular Journal</i> , 2019 , 53, 162-168	2	4
162	Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation. <i>Cardiovascular Diabetology</i> , 2019 , 18, 26	8.7	4
161	Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 94, 660-668	2.7	6
160	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2019 , 108, 133-141	6.1	4
159	Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2019 , 274, 348-350	3.2	8
158	High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes. <i>Atherosclerosis</i> , 2019 , 282, 183-187	3.1	3

157	The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 1097-1103	5.8	11
156	Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction. <i>EBioMedicine</i> , 2019 , 46, 264-273	8.8	14
155	Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia. <i>Circulation</i> , 2019 , 139, 2198-2211	16.7	28
154	Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). <i>Open Heart</i> , 2019 , 6, e001108	3	28
153	Response by Nytr�n et al to Letter Regarding Article, "Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia". <i>Circulation</i> , 2019 , 140, e735-e736	16.7	
152	Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial. <i>Transplantation</i> , 2019 , 103, 781-788	1.8	4
151	The Predictive Value of Depression in the Years After Heart Transplantation for Mortality During Long-Term Follow-Up. <i>Psychosomatic Medicine</i> , 2019 , 81, 513-520	3.7	5
150	Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression. <i>American Journal of Transplantation</i> , 2019 , 19, 1050-1060	8.7	5
149	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018 , 23, 303-323	5	27
148	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 888-895	12.3	65
147	The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 923-931	3.9	20
146	Health-related quality of life in older patients with acute coronary syndrome randomised to an invasive or conservative strategy. The After Eighty randomised controlled trial. <i>Age and Ageing</i> , 2018 , 47, 42-47	3	9
145	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , 2018 , 20, 268-277	12.3	25
144	The predictive value of coronary artery calcium detected by computed tomography in a prospective study on cardiac allograft vasculopathy in heart transplant patients. <i>Transplant International</i> , 2018 , 31, 82-91	3	9
143	Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 160	2.3	3
142	Age-dependent morbidity and mortality outcomes after surgical aortic valve replacement. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018 , 27, 650-656	1.8	4
141	Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. <i>ESC Heart Failure</i> , 2018 , 5, 1052-1059	3.7	1
140	Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial. <i>ESC Heart Failure</i> , 2018 , 5, 977-984	3.7	25

139	Response to the editor. <i>Heart Failure Reviews</i> , 2018 , 23, 819		5
138	Clinical features and determinants of VO in heart transplant recipients. <i>World Journal of Transplantation</i> , 2018 , 8, 188-197	2.3	5
137	Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis. <i>Open Heart</i> , 2018 , 5, e000901	3	0
136	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2309-2320	15.1	73
135	Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. <i>Open Heart</i> , 2018 , 5, e000765	3	7
134	Treatment of sleep apnea in patients with paroxysmal atrial fibrillation: design and rationale of a randomized controlled trial. <i>Scandinavian Cardiovascular Journal</i> , 2018 , 52, 372-377	2	6
133	Importance of physical capacity and the effects of exercise in heart transplant recipients. <i>World Journal of Transplantation</i> , 2018 , 8, 1-12	2.3	15
132	Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients. <i>Circulation: Heart Failure</i> , 2018 , 11, e004050	7.6	22
131	Author's response to: letter to the editor. <i>Heart Failure Reviews</i> , 2018 , 23, 819		5
130	Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1 in non-ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2018 , 271, 1-7	3.2	13
129	Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). <i>Biomarkers</i> , 2017 , 22, 261-267	2.6	6
128	Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy. <i>Biomarkers</i> , 2017 , 22, 367-371	2.6	18
127	Left Ventricular Contraction Pattern in Chronic Aortic Regurgitation and Preserved Ejection Fraction: Simultaneous Stress-Strain Analysis by Three-Dimensional Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2017 , 30, 422-430.e2	5.8	10
126	Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 981-989	3.9	21
125	Reproducibility of an extensive self-report questionnaire used in secondary coronary prevention. <i>Scandinavian Journal of Public Health</i> , 2017 , 45, 269-276	3	11
124	Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens. <i>Clinical Transplantation</i> , 2017 , 31, e12927	3.8	11
123	Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. <i>Heart</i> , 2017 , 103, 1521-1527	5.1	33
122	Connective tissue growth factor and bone morphogenetic protein 2 are induced following myocardial ischemia in mice and humans. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017 , 77, 321-331	2	5

121	Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2017 , 4, 133-149	4.4	21
120	The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2017 , 10, 401-410	3.3	12
119	Prognostic Value of Left Ventricular Deformation Parameters in Patients with Severe Aortic Stenosis: A Pilot Study of the Usefulness of Strain Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2017 , 30, 727-735.e1	5.8	23
118	Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017 , 5, 256-264	7.9	21
117	Wnt5a is elevated in heart failure and affects cardiac fibroblast function. <i>Journal of Molecular Medicine</i> , 2017 , 95, 767-777	5.5	34
116	NEIL3-Dependent Regulation of Cardiac Fibroblast Proliferation Prevents Myocardial Rupture. <i>Cell Reports</i> , 2017 , 18, 82-92	10.6	24
115	Optimal blood pressure control after coronary events: the challenge remains. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 823-830		4
114	Cognitive function among long-term survivors of heart transplantation. <i>Clinical Transplantation</i> , 2017 , 31, e13143	3.8	4
113	Medical and sociodemographic factors predict persistent smoking after coronary events. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 241	2.3	7
112	Newer Immunosuppression and Strategies on the Horizon in Heart Transplantation. <i>Current Transplantation Reports</i> , 2017 , 4, 226-237	1.5	
111	Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE). <i>Clinical Transplantation</i> , 2017 , 31, e13038	3.8	2
110	The role of cardiac rehabilitation in secondary prevention after coronary events. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1360-1368	3.9	22
109	Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017 , 23, 666-671	3.3	53
108	Morbidity outcomes after surgical aortic valve replacement. <i>Open Heart</i> , 2017 , 4, e000588	3	11
107	Unfavourable risk factor control after coronary events in routine clinical practice. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 40	2.3	10
106	Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy. <i>Scientific Reports</i> , 2017 , 7, 3490	4.9	20
105	Long-term effects of high-intensity interval training in heart transplant recipients: A 5-year follow-up study of a randomized controlled trial. <i>Clinical Transplantation</i> , 2017 , 31, e12868	3.8	22
104	Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients. <i>Open Heart</i> , 2017 , 4, e000635	3	12

103	Determinants and Outcome of Decision Making Among Patients with Severe Aortic Stenosis. <i>Journal of Heart Valve Disease</i> , 2017 , 26, 413-422		1
102	Exercise capacity and peak oxygen consumption in asymptomatic patients with chronic aortic regurgitation. <i>International Journal of Cardiology</i> , 2016 , 223, 688-692	3.2	8
101	Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation. <i>Transplant Immunology</i> , 2016 , 38, 75-7	1.7	6
100	Comparison of simplified and comprehensive methods for assessing the index of microvascular resistance in heart transplant recipients. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, 283-307		
99	Validity of standard gamble utilities in patients referred for aortic valve replacement. <i>Quality of Life Research</i> , 2016 , 25, 1703-12	3.7	7
98	Patient characteristics and risk factors of participants and non-participants in the NOR-COR study. <i>Scandinavian Cardiovascular Journal</i> , 2016 , 50, 317-322	2	4
97	Peak oxygen uptake and self-reported physical health are strong predictors of long-term survival after heart transplantation. <i>Clinical Transplantation</i> , 2016 , 30, 161-9	3.8	39
96	Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1057-1065	4.0	232
95	The role of medical and psychosocial factors for unfavourable coronary risk factor control. <i>Scandinavian Cardiovascular Journal</i> , 2016 , 50, 1-8	2	18
94	Controlled release metoprolol for aortic regurgitation: a randomised clinical trial. <i>Heart</i> , 2016 , 102, 191-5	3.1	12
93	Increased Serum Levels of the Notch Ligand DLL1 are Associated with Diastolic Dysfunction, Reduced Exercise Capacity, and Adverse Outcome in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016 , 22, 218-23	3.3	15
92	Design and rationale of the HITTs randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia. <i>American Heart Journal</i> , 2016 , 172, 96-103	4.9	10
91	Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. <i>Transplant International</i> , 2016 , 29, 819-29	3	26
90	Eliciting Patient Risk Willingness in Clinical Consultations as a Means of Improving Decision-Making of Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2016 , 5, e002828	6	8
89	Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016 , 22, 823-8	3.3	12
88	Index of microvascular resistance after early conversion from calcineurin inhibitor to everolimus in heart transplantation: A sub-study to a 1-year randomized trial. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 1010-7	5.8	4
87	Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. <i>European Heart Journal</i> , 2016 , 37, 2406-13	9.5	172
86	Contemporary Outcome in Patients With Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015 , 116, 952-9	3	14

85	Osteoprotegerin concentrations in patients with suspected reversible myocardial ischemia: observations from the Akershus Cardiac Examination (ACE) 1 Study. <i>Cytokine</i> , 2015 , 73, 122-7	4	1
84	Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2015 , 16, 217-24 ¹	4.1	75
83	Results of comprehensive diagnostic work-up in Idiopathic Dilated cardiomyopathy. <i>Open Heart</i> , 2015 , 2, e000271	3	4
82	Altered Levels of Fatty Acids and Inflammatory and Metabolic Mediators in Epicardial Adipose Tissue in Patients With Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2015 , 21, 916-23	3.3	16
81	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 31-6	6.4	19
80	The Notch ligand Delta-like 1 is elevated and associated with mortality in patients with symptomatic aortic stenosis. <i>International Journal of Cardiology</i> , 2015 , 180, 18-20	3.2	6
79	Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure. <i>International Journal of Cardiology</i> , 2015 , 179, 378-84	3.2	24
78	Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>PLoS ONE</i> , 2015 , 10, e0133970	3.7	17
77	Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice. <i>PLoS ONE</i> , 2015 , 10, e0139715	3.7	11
76	Elevated inflammatory markers in preeclamptic pregnancies, but no relation to systemic arterial stiffness. <i>Pregnancy Hypertension</i> , 2015 , 5, 325-9	2.6	13
75	Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes—a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2015 , 15, 147	2.3	8
74	Inflammatory cytokines as biomarkers in heart failure. <i>Clinica Chimica Acta</i> , 2015 , 443, 71-7	6.2	68
73	Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls. <i>Journal of Diabetes</i> , 2015 , 7, 779-90	3.8	17
72	Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. <i>Journal of Cardiac Failure</i> , 2015 , 21, 153-9	3.3	10
71	Sleep-disordered Breathing in Heart Failure - Current State of the Art. <i>Cardiac Failure Review</i> , 2015 , 1, 16-24	4.2	1
70	Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. <i>Current Heart Failure Reports</i> , 2014 , 11, 146-55	2.8	37
69	One year of high-intensity interval training improves exercise capacity, but not left ventricular function in stable heart transplant recipients: a randomised controlled trial. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 181-91	3.9	35
68	Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 289-97	7.9	84

67	CXCR4 blockade induces atherosclerosis by affecting neutrophil function. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 74, 44-52	5.8	36
66	Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 187-97	7.9	24
65	Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart. <i>Life Sciences</i> , 2014 , 97, 145-54	6.8	26
64	Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and B̈um Cardiovascular Diabetes (ABCD) study. <i>American Heart Journal</i> , 2014 , 168, 280-288.e2	4.9	13
63	The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial. <i>PLoS ONE</i> , 2014 , 9, e89732	3.7	8
62	The homeostatic chemokine CCL21 predicts mortality in aortic stenosis patients and modulates left ventricular remodeling. <i>PLoS ONE</i> , 2014 , 9, e112172	3.7	13
61	Muscular exercise capacity and body fat predict VO ₂ peak in heart transplant recipients. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 21-9	3.9	22
60	Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. <i>European Journal of Heart Failure</i> , 2014 , 16, 68-75	12.3	46
59	Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease. <i>Heart</i> , 2014 , 100, 1793-8	5.1	5
58	Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E ₂ -related mechanisms and enhance the anti-inflammatory effects of CXCL13. <i>Atherosclerosis</i> , 2014 , 234, 352-9	3.1	18
57	Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). <i>JACC: Heart Failure</i> , 2014 , 2, 35-40	7.9	21
56	Effect of high-intensity interval training on progression of cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2013 , 32, 1073-80	5.8	41
55	Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and B̈um Cardiovascular Diabetes (ABCD) cohort study. <i>Cardiovascular Diabetology</i> , 2013 , 12, 126	8.7	34
54	Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013 , 168, 212-8	3.2	20
53	Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. <i>International Journal of Cardiology</i> , 2013 , 167, 1892-9	3.2	41
52	Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>Circulation: Heart Failure</i> , 2013 , 6, 91-8	7.6	37
51	Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease. <i>Circulation: Heart Failure</i> , 2013 , 6, 443-50	7.6	22
50	Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. <i>Circulation: Heart Failure</i> , 2013 , 6, 219-26	7.6	153

49	Exercise after heart transplantation: An overview. <i>World Journal of Transplantation</i> , 2013 , 3, 78-90	2.3	49
48	Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease. <i>Scandinavian Cardiovascular Journal</i> , 2012 , 46, 23-31	2	3
47	Inflammatory cytokines in heart failure: mediators and markers. <i>Cardiology</i> , 2012 , 122, 23-35	1.6	220
46	The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>American Heart Journal</i> , 2012 , 164, 878-83	4.9	74
45	The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure. <i>PLoS ONE</i> , 2012 , 7, e33038	3.7	20
44	Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2012 , 33, 2290-6	9.5	110
43	Galectin-3 in heart failure: high levels are associated with all-cause mortality. <i>International Journal of Cardiology</i> , 2011 , 150, 361-4	3.2	65
42	Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. <i>Transplantation</i> , 2011 , 92, 235-43	1.8	63
41	Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. <i>Circulation: Heart Failure</i> , 2011 , 4, 145-52	7.6	50
40	Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload. <i>PLoS ONE</i> , 2011 , 6, e18668	3.7	21
39	Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 641-7	5.8	38
38	Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. <i>Transplantation</i> , 2010 , 89, 864-72	1.8	106
37	Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. <i>Transplantation</i> , 2010 , 90, 1581-9 ^{1.8}		53
36	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009 , 11, 119-29	12.3	248
35	Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. <i>Circulation: Heart Failure</i> , 2009 , 2, 624-32	7.6	32
34	Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. <i>Circulation</i> , 2009 , 120, 2188-96	16.7	138
33	Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2008 , 45, 261-9	5.8	60
32	The role of statins in heart failure. <i>Fundamental and Clinical Pharmacology</i> , 2007 , 21 Suppl 2, 35-40	3.1	6

31	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , 2007 , 357, 2248-61	59.2	1098
30	Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. <i>Transplantation</i> , 2007 , 84, 149-54	1.8	44
29	Depressive symptoms and all-cause mortality after heart transplantation. <i>Transplantation</i> , 2007 , 84, 97-103	103	47
28	Potential mechanisms of benefit with thalidomide in chronic heart failure. <i>American Journal of Cardiovascular Drugs</i> , 2007 , 7, 127-34	4	5
27	Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 857-63	9.4	153
26	The role of intravenous immunoglobulin in the treatment of chronic heart failure. <i>International Journal of Cardiology</i> , 2006 , 112, 40-5	3.2	26
25	Systemic inflammation in heart failure--the whys and wherefores. <i>Heart Failure Reviews</i> , 2006 , 11, 83-92	5	208
24	Agents targeting inflammation in heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 557-66	5.9	31
23	Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. <i>American Journal of Cardiology</i> , 2005 , 95, 17C-23C; discussion 38C-40C	3	93
22	Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. <i>Circulation</i> , 2005 , 111, 2461-8	16.7	186
21	Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. <i>Circulation</i> , 2005 , 112, 3408-14	16.7	65
20	Inflammation in coronary artery disease: potential role for immunomodulatory therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 1111-24	2.5	11
19	Elevated levels of activin A in heart failure: potential role in myocardial remodeling. <i>Circulation</i> , 2004 , 109, 1379-85	16.7	126
18	Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. <i>Autoimmunity</i> , 2004 , 37, 489-93	3	13
17	Therapeutic potential of anticytokine therapy in congestive heart failure. <i>American Journal of Cardiovascular Drugs</i> , 2004 , 4, 169-77	4	9
16	Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1970-6	15.1	148
15	Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipients. <i>American Heart Journal</i> , 2004 , 147, 49-54	4.9	26
14	Immunomodulating therapy: new treatment modality in congestive heart failure. <i>Congestive Heart Failure</i> , 2003 , 9, 64-9		11

13	Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. <i>Cardiovascular Research</i> , 2003 , 60, 141-6	9.9	119
12	Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. <i>Cardiovascular Research</i> , 2002 , 54, 175-82	9.9	72
11	Effect of thalidomide in patients with chronic heart failure. <i>American Heart Journal</i> , 2002 , 144, 847-50	4.9	42
10	Cytokines as new treatment targets in chronic heart failure. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001 , 2, 271-277		34
9	Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. <i>American Journal of Cardiology</i> , 2001 , 87, 815-8, A9	3	63
8	Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. <i>Circulation</i> , 2001 , 103, 220-5	16.7	263
7	Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 187-93	15.1	82
6	Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). <i>American Heart Journal</i> , 2001 , 141, 418-21	4.9	51
5	Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. <i>Circulation</i> , 2001 , 104, 1494-500	16.7	59
4	Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. <i>Circulation</i> , 1999 , 100, 614-20	16.7	451
3	Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1999 , 83, 376-82	3	390
2	Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 2061-7	15.1	193
1	Elevated circulating levels of C-C chemokines in patients with congestive heart failure. <i>Circulation</i> , 1998 , 97, 1136-43	16.7	293